Towards personalized tumor markers

Abstract The cancer biomarker discovery pipeline is progressing slowly. The difficulties of finding novel and effective biomarkers for diagnosis and management of cancer patients are well-known. We speculate that it is unlikely to discover new serological biomarkers characterized by high sensitivity...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vathany Kulasingam, Ioannis Prassas, Eleftherios P. Diamandis
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e17bc80beb4f4e19b16255e97dc4774b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e17bc80beb4f4e19b16255e97dc4774b
record_format	dspace
spelling	oai:doaj.org-article:e17bc80beb4f4e19b16255e97dc4774b2021-12-02T13:41:45ZTowards personalized tumor markers10.1038/s41698-017-0021-22397-768Xhttps://doaj.org/article/e17bc80beb4f4e19b16255e97dc4774b2017-05-01T00:00:00Zhttps://doi.org/10.1038/s41698-017-0021-2https://doaj.org/toc/2397-768XAbstract The cancer biomarker discovery pipeline is progressing slowly. The difficulties of finding novel and effective biomarkers for diagnosis and management of cancer patients are well-known. We speculate that it is unlikely to discover new serological biomarkers characterized by high sensitivity and specificity. This projection is supported by recent findings that cancers are genetically highly heterogeneous. Here, we propose a new way of improving the landscape of cancer biomarker research. There are currently hundreds, if not thousands, of described biomarkers which perform at high specificity (> 90%), but at relatively low sensitivity (< 30%). We call these “rare tumor markers.” Borrowing from the principles of precision medicine, we advocate that among these low sensitivity markers, some may be useful to specific patients. We suggest screening new patients for hundreds to thousands of cancer biomarkers to identify a few that are informative, and then use them clinically. This is similar to what we currently do with genomics to identify personalized therapies. We further suggest that this approach may explain as to why some biomarkers are elevated in only a small group of patients. It is likely that these differences in expression are linked to specific genomic alterations, which could then be found with genomic sequencing.Vathany KulasingamIoannis PrassasEleftherios P. DiamandisNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 1, Iss 1, Pp 1-4 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Vathany Kulasingam Ioannis Prassas Eleftherios P. Diamandis Towards personalized tumor markers
description	Abstract The cancer biomarker discovery pipeline is progressing slowly. The difficulties of finding novel and effective biomarkers for diagnosis and management of cancer patients are well-known. We speculate that it is unlikely to discover new serological biomarkers characterized by high sensitivity and specificity. This projection is supported by recent findings that cancers are genetically highly heterogeneous. Here, we propose a new way of improving the landscape of cancer biomarker research. There are currently hundreds, if not thousands, of described biomarkers which perform at high specificity (> 90%), but at relatively low sensitivity (< 30%). We call these “rare tumor markers.” Borrowing from the principles of precision medicine, we advocate that among these low sensitivity markers, some may be useful to specific patients. We suggest screening new patients for hundreds to thousands of cancer biomarkers to identify a few that are informative, and then use them clinically. This is similar to what we currently do with genomics to identify personalized therapies. We further suggest that this approach may explain as to why some biomarkers are elevated in only a small group of patients. It is likely that these differences in expression are linked to specific genomic alterations, which could then be found with genomic sequencing.
format	article
author	Vathany Kulasingam Ioannis Prassas Eleftherios P. Diamandis
author_facet	Vathany Kulasingam Ioannis Prassas Eleftherios P. Diamandis
author_sort	Vathany Kulasingam
title	Towards personalized tumor markers
title_short	Towards personalized tumor markers
title_full	Towards personalized tumor markers
title_fullStr	Towards personalized tumor markers
title_full_unstemmed	Towards personalized tumor markers
title_sort	towards personalized tumor markers
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/e17bc80beb4f4e19b16255e97dc4774b
work_keys_str_mv	AT vathanykulasingam towardspersonalizedtumormarkers AT ioannisprassas towardspersonalizedtumormarkers AT eleftheriospdiamandis towardspersonalizedtumormarkers
_version_	1718392586366877696

Towards personalized tumor markers

Ejemplares similares